Hypothalamic-Locus Coeruleus Mechanisms in the Pathophysiology of “On-Off” in L-Dopa Treated Parkinson's Disease: A Hypothesis

References

• Banerjee S. P., Kung L. S., Riggi S. J., Chanda S. K. Development of beta-adrenergic receptor subsensitivity by antidepressants. Nature 1974; 268: 455–456
   Google Scholar
• Barbeau A. the clinical physiology of side effects in long-term L-dopa therapy. Advances in Neurology, F. H. McDowell, A. Barbeau. Raven Press, New York 1974; Vol. 5: 347
   Google Scholar
• Barbeau A. Pathophysiology of the oscillations in performance after long-term theraphy with L-dopa. Advances in Parkinsonism, W. Birkmayer, O. Hornykiewicz. Editiones, Basel 1976; 424–434
   Google Scholar
• Bjorklund A., Stenevi U. Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system. Physiological Review 1979; 59: 62–100
   PubMed Web of Science ®Google Scholar
• Bjorklund A., Lindvall O. Regeneration of normal terminal innervation patterns by central noradrenergic neurons after 5,7-dihydroxytryptamine-induced axonotomy in the adult rat. Brain Research 1979; 171: 271–294
   PubMed Web of Science ®Google Scholar
• Calne D., Stern G., Lawrence D., Sharkey J., Armitage P. L-dopa in postencephalitic Parkinsonism. Lancet 1969; 1: 744–745
   PubMed Web of Science ®Google Scholar
• Corrodi H., Fuxe K., Ljungdahl A., Ogren S. O. Studies on the action of some psychoactive drugs on central noradrenaline neurons after inhibiton of dopamine beta-hydroxylase. Brain Research 1970; 24: 451–470
   PubMedGoogle Scholar
• Duvoisin R. C. Levodopa-induced involuntary movements. Advances in Parkinsonism, W. Birkmayer, O. Hornykiewicz. Editiones, Basel 1976; 574–581
   Google Scholar
• Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. Movement disorders, C. D. Marsden, S. Fahn. Butterworth Scientific, London 1982; 123–145
   Google Scholar
• Foote S. L., Aston-Jones G., Bloom F. E. Impulse activity of locus coeruleus in awake rats and monkeys is a function of sensory stimulation and arousal. Proceedings of the National Academy of Sciences 1980; 77: 3033–3037
   PubMed Web of Science ®Google Scholar
• Goldstein M., Battista A., Ohmoto T., Anagnoste B., Fube K. Tremor and involuntary movements in monkeys. Science 1973; 179: 816–819
   PubMed Web of Science ®Google Scholar
• Guttman M., Seeman P., Reynolds G. P. Dopamine D2 receptor density remains constant in treated Parkinsons's disease. Annals of Neurology 1986; 19: 487–492
   PubMed Web of Science ®Google Scholar
• Jerussi T. P., Capacchione J. F., Benvenga M. J. Reversal of opioid-induced muscular rigidity in rats: Evidence for alpha-2 adrenergic involvement. Pharmacology, Biochemistry & Behavior 1987; 28: 283–289
   PubMed Web of Science ®Google Scholar
• Jonsson G., Pycock C., Fuxe K., Sachs C. Changes in the development of cental noradrenaline neurons following neonatal administration of 6-hydroxydopamine. Journal of Neurochemistry 1974; 22: 419–426
   PubMed Web of Science ®Google Scholar
• Jouvet M. The role of monoamines and acetycholine containing neurons in the regulation of the sleep-waking cycle. Ergebnisse der Physiologie 1972; 64: 166–307
   PubMedGoogle Scholar
• Kurlan R. Dietary therapy for motor fluctuations in Parkinson's disease. Archives of Neurology 1987; 44: 1119–1121
   PubMedGoogle Scholar
• Levitt P., Moore R. Y. Origin and organization of brainstem catecholamine innervation in the rat. Journal of Comparative Neurology 1979; 186: 505–528
   PubMed Web of Science ®Google Scholar
• McDowell F. H., Sweet R. D. The on-off phenomenon. Advances in Parkinsonism, W. Birkmayer, O. Hornykiewicz. Editiones, Basel 1976; 603–612
   Google Scholar
• Marsden C. D., Dolphin A., Duvoisin R. C, Jenner P., Tarsy D. Role of noradrenaline in lovodopa reversal of reserpine akinesia. Brain Research 1974; 77: 521–525
   PubMed Web of Science ®Google Scholar
• Miller M. M., Dement W. C. Catapletic-like behavior in cats after microinjection of carbachol in pontine reticular formation. Brain Research 1974; 68: 335–343
   PubMed Web of Science ®Google Scholar
• Nagatsu T., Kato T., Nagatsu I., Kondo Y., Inagaki S., Iizuka R., Narabayashi H. Catecholamine-related enzymes in the brain of Parkinsonian patients. Catecholamines: basic and clinical frontiers, E. Usdin, I. J. Kopin, J. Barchas. Pergamon Press, New York 1979; 1587–1589
   Google Scholar
• Petraglia G., Nappi F., Martignoni E., Facchinetti F, Bono G., Genazzani A. R. Beta-endorphin cerebrospinal fluid decrease in untreated Parkinsonian patients. Neurology 1985; 35: 1371–1374
   PubMed Web of Science ®Google Scholar
• Narabayashi H., Kondo T., Yokochi F., Nagatsu T. Clinical effects of L-threo-3,4-dihydroxphenylserine in cases of parkinsonism and pure akinesia. Advances in Neurology, M. D. Yahr, K. J. Bergman. Raven Press, New York 1986; vol. 45: 593–602
   Google Scholar
• Parkes J., Marsden C. D., Rees J., Kantamaneni G., Curzpn B., Knill-Jones R., Akbar A., Das S., Katania M. Parkinson's disease, cerebral arteriosclerosis and senile dementia. Quarterly Journal of Medicine 1974; 48: 49–58
   Google Scholar
• Pert C. B., Kuhar M. J., Snyder S. H. Autoradiographic localization of the opiate receptor in rat brain. Life Sciences 1975; 16: 1849–1854
   PubMed Web of Science ®Google Scholar
• Riederer P., Birkmayer W., Rausch W. D., Jellinger K., Danielczyk W. CNS and adrenal gland tyrosine hydroxylase and the influence of drug treatment on cAMP activity in Parkinson's disease. Human post-mortem studies. Catecholamines: basic and clinical frontiers, E. Usdin, I. J. Kopin, J. Barchas. Pergamon Press, New York 1979; 1625–1628
   Google Scholar
• Rinne U. K., Sonninen V. Brain catecholamines and their metabolites in parkinsonian patients. Archives of Neurology 1973; 28: 107–110
   PubMedGoogle Scholar
• Sandyk R. The endogenous opioids in neurological disorders of the basal-ganglia. Life Sciences 1985; 37: 1655–1663
   PubMed Web of Science ®Google Scholar
• Sandyk R., Consroe P. ACTH and trauma-induced dystonia. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 845
   PubMed Web of Science ®Google Scholar
• Sandyk R., Snider S. R. Sensory symptoms in Parkinson's disease. neurology 1985; 35: 619–620
   PubMed Web of Science ®Google Scholar
• Strahlendorf H. K., Strahlendorf J. C., Barnes C. D. Endorphin-mediated inhibition of locus coeruleus. Brain Research 1980; 191: 284–288
   PubMed Web of Science ®Google Scholar
• Sulser F., Ventulani J., Mobley P. L. Mode of action of antidepressant drugs. Biochemical Pharmacology 1978; 27: 257–261
   PubMed Web of Science ®Google Scholar
• Sweet R., McDowell F. H. Plasma dopa levels on the on-off effects in Parkinson's disease. Neurology 1974; 10: 953–957
   Google Scholar
• Trabucchi M., Bassi S., Fratolla L. Effect of naloxone on the on-off syndrome in patients receiving long-term levodopa theraphy. Archives of Neurology 1982; 39: 120–121
   PubMedGoogle Scholar
• Van Dongen P. A. M. The human locus coeruleus in neurology and psychiatry. Progress in Neurobiology 1981; 17: 97–139
   PubMed Web of Science ®Google Scholar
• Van Dongen P. A. M. The central noradrenergic transmission and the locus coeruleus: a review of the data and their implications for neurotransmission and neuromodulation. Progress in Neurobiology 1981; 16: 117–143
   PubMed Web of Science ®Google Scholar